The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1138
September 2, 2002
View Complete Issue         Table of Contents 2019 
Gefitinib (Iressa) for advanced non-small cell lung cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gefitinib (Iressa) for advanced non-small cell lung cancer
September 2, 2002 (Issue: 1138)
Patients with lung cancer may be asking their physicians about gefitinib (ge fi' tye nib; ZD1839; Iressa -- AstraZeneca), because it has been the subject of positive coverage in the media. An inhibitor of the epidermal growth factor receptor (EGFR)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gefitinib (Iressa) for advanced non-small cell lung cancer
Article code: 1138b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.